TP53 and breast cancer: Similar findings of a high prevalent detection rate was found in the MARIBS study [22, 23] (which included TP53 mutation carriers) with 2.7% of 632 women detected with breast cancer at prevalent screen dropping to 1.2% at the first incident round.